Megestrol

A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Also Known As:

Networked: 112 relevant articles (15 outcomes, 28 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gescher, Dorothee M: 2 articles (01/2006 - 12/2003)
2.	Goedeken, Birgit: 2 articles (01/2006 - 12/2003)
3.	Jahn, Holger: 2 articles (01/2006 - 12/2003)
4.	Kellner, Michael: 2 articles (01/2006 - 12/2003)
5.	Raedler, Thomas J: 2 articles (01/2006 - 12/2003)
6.	Wiedemann, Klaus: 2 articles (01/2006 - 12/2003)
7.	García García, Emilio: 1 article (11/2022)
8.	Quiroga Cantero, Eduardo: 1 article (11/2022)
9.	Ramírez Villar, Gema Lucía: 1 article (11/2022)
10.	Brangman, Sharon A: 1 article (07/2022)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 08/24/1994 - "Postmenopausal women unable to take oestrogens because they have breast cancer might gain relief from hot flushes by taking megestrol." 11/01/2003 - "An economic model was developed based on data from phase III megestrol-controlled clinical trials of antiaromatase agents (AA) and estimates of resource utilization from both Statistic Canada's Population Health Model for breast cancer and expert opinion. " 10/01/2000 - "Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol." 06/01/1991 - "The next generation of adjuvant trials in breast cancer needs to explore the potential of an alternating tamoxifen/megestrol regimen." 01/01/2002 - "Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia."
2.	Disease Progression 07/31/2002 - "On the other hand, megestrol, a drug able to block both the wild type and the variant form of ER, influence the clinical course of HCC presenting vER. " 06/01/2000 - "However, the duration of overall success and times to disease progression and treatment failure were significantly prolonged with exemestane compared with megestrol. " 10/01/1999 - "Results from a phase III trial indicate that exemestane achieves a similar objective response rate to megestrol as a second-line therapy; however, exemestane achieved a significantly longer duration of overall success, time to disease progression and survival time. " 06/01/2000 - "Exemestane is effective in postmenopausal patients with tamoxifen-refractory advanced breast cancer, prolonging time to disease progression and treatment failure and improving survival compared with megestrol treatment. " 01/01/2006 - "In women with hormone-responsive advanced breast cancer, letrozole is superior to tamoxifen in prolonging the time to disease progression and time to treatment failure in a first-line setting, and is at least as effective as anastrozole and more effective than megestrol for some endpoints (in one of two trials) in a second-line setting. "
3.	Hepatocellular Carcinoma (Hepatoma) 04/06/2001 - "Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (P = 0.0090). " 01/01/2018 - "Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature." 11/16/2001 - "Megestrol treatment in patients with hepatocellular carcinoma." 04/06/2001 - "Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors." 02/01/2010 - "Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era."
4.	Hot Flashes 12/01/2004 - "Megestrol has also been used as an appetite stimulant for patients with human immunodeficiency virus and malignancy who experience cachexia and wasting; also, megestrol can be beneficial in relieving hot flashes in women and men. " 06/01/2002 - "depot MPA injections provides significant and long-lasting relief from postmenopausal hot flashes in patients with a history of breast cancer, offering an alternative to estrogen replacement therapy or prolonged administration of oral megestrol." 06/01/2002 - "Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study."
5.	Neoplasms (Cancer) 04/30/1995 - "The results of the study indicate comparable efficacy (using tumor clearance as an end point) of DES and Megestrol. " 03/01/1989 - "The results of the study indicate comparable efficacy (using tumor clearance as an end-point) of DES and Megestrol. " 02/01/2010 - "At 3 months, tumor burden was more frequently stable with megestrol, while performance status was significantly better in patients treated with Synchro-Levels. " 02/01/2010 - "Most patients had multifocal disease (75% in megestrol and 59% in Synchro-Levels) and there was a significant difference in tumor burden, with more advanced disease in the megestrol arm (P = 0.0002). " 11/01/2005 - "A 21- x 18-mm residual area of neoplasm in the lung completely resolved 3 months after treatment with megestrol. "

Related Drugs and Biologics

1.	Tamoxifen
2.	Gonadotropin-Releasing Hormone (GnRH)
3.	Anastrozole (Arimidex)
4.	Hormones (Hormone)
5.	Letrozole (Femara)
6.	Medroxyprogesterone
7.	exemestane (Aromasin)
8.	Contraceptive Agents (Contraceptives)
9.	nedaplatin
10.	Metformin (Glucophage)

Related Therapies and Procedures

1.	Therapeutics
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Time-to-Treatment
4.	Endometrial Ablation Techniques
5.	Chemoradiotherapy